Exelixis Inc (EXEL)vsRevolution Medicines Inc (RVMD)
EXEL
Exelixis Inc
$52.49
-0.24%
HEALTHCARE · Cap: $13.35B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Exelixis Inc generates 320047% more annual revenue ($2.38B vs $742,000). EXEL leads profitability with a 35.1% profit margin vs 0.0%. EXEL earns a higher WallStSmart Score of 72/100 (B).
EXEL
Strong Buy72
out of 100
Grade: B
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.2%
Fair Value
$161.90
Current Price
$52.49
$109.41 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 43 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 41.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 41.1%.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
EXEL profiles as a mature stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
EXEL is growing revenue faster at 10.0% — sustainability is the question.
EXEL generates stronger free cash flow (250M), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (72/100 vs 24/100), backed by strong 35.1% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?